Case-Control Study of Inflammatory Cytokines and Chemokines in Hematogenic Thrombophilia

Islamov Miralisher Sadriddinovich¹, Makhmudova Azizа Dzhumanovna¹, Kayumov Abdurakhmon Abdumavlyanovich¹ and Berger Inna Viktorovna^1,

¹Republican Specialized Scientific and Practical Medical Center of Hematology, Tashkent, Uzbekistan

Cite this paper:
Islamov Miralisher Sadriddinovich, Makhmudova Azizа Dzhumanovna, Kayumov Abdurakhmon Abdumavlyanovich and Berger Inna Viktorovna. Case-Control Study of Inflammatory Cytokines and Chemokines in Hematogenic Thrombophilia. American Journal of Medical Sciences and Medicine. 2023; 11(2):64-66. doi: 10.12691/ajmsm-11-2-4

Abstract

The aim of the work was to study the parameters of hemostasis and their pathogenetic relationship with pro-inflammatory cytokines in hematogenous thrombophilia. Materials and methods: to solve the problem, a prospective study was conducted for the period 2021-2022. The main group included 47 patients registered with the RSSPMC of hematology with diagnoses of chronic leukemia included in the group. The selected patients were aged 18 to 45 years with a history of thrombosis and 36 patients with thrombosis at the moment. The comparison group consisted of 30 practically healthy people. Results and conclusions: At present, in patients with thrombosis, the intensity of the synthesis of positive factors IL-6 and IL-8 prevails over the synthesis of other cytokines, while in the synthesis of negative cytokines TNFα significantly prevails, which apparently determines the severity of thrombosis. A pathogenetic relationship between increased IL-1β, TNF-α, and activation of procoagulant mechanisms in the blood of patients suffering from acute thrombosis was revealed.

Keywords:
chronic leukemia cytokines interleukins hemostasis thrombosis

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Arachchillage D.J., Mackillop L., Chandratheva A., Motawani J., MacCallum P., Laffan M. Thrombophilia testing: A British Society for Haematology guideline // Br. J. Haematol. - 2022. - Vol.198, N3. – P.443-458.
[2]	Bierings R., van den Biggelaar M., Kragt A. et al. Efficiency of von Willebrand factor-mediated targeting of interleukin-8 into Weibel-Palade bodies // J. Thromb. haemost. - 2017. - Vol. 5, No 12. - P. 2512-2519.
[3]	Blinova E.A., Grebennikova I.V. Etiology and pathogenesis of thrombophilia // International Student Scientific Bulletin. - 2016. - No. 4-2. - P.143-144.
[4]	De Palma C., Meacci F., Perrotta C. et al. Endothelial nitric oxide synthase activation by tumor necrosis factor-a // Arterioscler. Thromb. Vasc. Biol. - 2016. - No 1. - P. 99–106.
[5]	Edelev D. A., Vitkovsky Yu. A., Kuznik B. I. Influence of interleukins 4 and 10 on blood clotting and fibrinolysis // Thrombosis, hemostasis and rheology. - 2020. - No 3. - S. 27–30.
[6]	Filatova E.A., Yesenina T.V., Mishkurova K.M., Fedorova N.A. Hereditary hematogenous thrombophilia, manifesting pulmonary embolism // Amur Med. Journal. - 2018. - No. 1-2 (20-21). - P.25-29.
[7]	Samoilenko V.V. Thrombophilia: diagnosis and treatment. Place and role of laboratory diagnostics // Thrombosis and thrombophilia in the practice of a phlebologist. Scientific-practical. conf. - M., 2018. - C.24-26.
[8]	Szotowski B., Antoniak S., Poller W. et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines // Cir. Res. - 2019. - No 12. - P. 1233–1239.
[9]	Vasiliev S.A., Vinogradov V.L., Smirnov A.N. Thrombosis and thrombophilia: classification, diagnosis, treatment, prevention // RMJ. Medical review. - 2013. - V.21, No. 17. - P.896.
[10]	Vorobyov A.I., Vasiliev S.A., Gorodetsky V.M., Shavelov A.A., Gorgidze L.A., Kremenetskaya O.S., Shklovsky-Kordi H.E. Hypercoagulation syndrome: classification, pathogenesis, diagnosis, therapy // Hematology and transfusiology. - 2016. - No. 3. - P.116-122.